Barclays takes a neutral position on
Gilead Sciences, despite the company's strategic refocus. Gilead Sciences' valuation and share price performance have been erratic, and the company's position has been reduced by the
Aberdeen Group plc. Despite trailing the market, the company has moved up with various investment outfits considerably raising their stake in Gilead Sciences.
HF Advisory Group LLC,
Nisa Investment Advisors LLC, Moody Lynn & Lieberson LLC, Banque Pictet & Cie SA, Allspring Global Investments Holdings LLC, and Meyer Handelman Co. all significantly raised their holdings of Gilead Sciences stock. Even though the company had a dip more than the broader market, it continuously outperformed it; Gilead's CEO sold 10,000 shares under the 10b5-1 plan. Many analysts back Gilead Sciences' growth prospects, causing several company valuations after the strong share price run. Moreover, the company's stock is considered a strong value with
Morgan Stanley speculating Gilead Sciences will thrive in 2026 amidst biopharma policy uncertainties. The company's potential was additionally confirmed by the announcement of an agreement to acquire
Ouro Medicines.
Gilead Sciences GILD News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Fri, 03 Apr 2026 23:10:19 GMT -
Rating 5
- Innovation 3
- Information 8
- Rumor -2
